The roots for the establishment of the ISPE Netherlands Affiliate of ISPE go back to the very first ISPE European congress as organized in Brussels in 1988. Quite a few people from the Netherlands attended that congress and were caught by the ISPE-spirit and ambitions.
The roots for the establishment of the ISPE Netherlands Affiliate of ISPE go back to the very first ISPE European congress as organized in Brussels in 1988. Quite a few people from the Netherlands attended that congress and were caught by the ISPE-spirit and ambitions.
ISPE Women in Pharma ®’s dedication to diversity, equity, and Inclusion isn't just about aspirations: it’s about action. Mentor ISPE, launched in 2023 by members for members
The 2024 ISPE Annual Meeting & Expo is the pharmaceutical industry’s gateway to discovering the latest trends, technologies, and best practices shaping the future of
Miriam Kremer-van der Kamp is the Business Developer at VILS Switzerland GmbH and an active ISPE member with the ISPE Germany/Austria/Switzerland (DACH) Affiliate, ISPE Women
This training course focuses on common issues and problems in the operation of a facility and maintaining readiness for cGMP inspection. Topics include control system alarm...
UK4 is a biological drug substance manufacturing facility that was designed and built under a “Three Zeros for Sustainable Development” concept. The three zeros encompass: 1) zero halogenated hydrocarbons, 2) zero...
Attend the 2024 ISPE Annual Meeting & Expo Our comprehensive education program offers cutting-edge technical sessions, shedding light on the latest advancements in areas like supply chain, operations, facilities, and...
This signature gathering is not just an opportunity to learn but also to connect. From emerging talents to seasoned executives in drug manufacturing, supply chain, devices and equipment and services, and global...
The explosive growth of advanced therapy medicinal products (ATMPs), particularly cellular therapeutics, has driven steady investment in facilities capable of manufacturing these therapeutics at scale . Meanwhile, the industry is collectively moving to adapt to...